Tumor necrosis factor alpha (TNF-α) is a pleiotropic cytokine with dual roles in cancer: it can promote tumor cell death at high concentrations but also drive chronic inflammation, angiogenesis, and metastasis at the lower concentrations typically found in the tumor microenvironment.
TNF-α signals through two receptors: TNFR1 (ubiquitous; mediates apoptosis and NF-κB activation) and TNFR2 (immune cells; promotes cell survival and Treg expansion). This dual biology makes TNF-α one of the most complex cytokines in cancer research. TNF-α belongs to the same TNF superfamily as the costimulatory targets OX40 and 4-1BB.
Anti-TNF therapeutics (adalimumab, infliximab, etanercept, golimumab, certolizumab) are among the most commercially successful biologic drugs globally, primarily for autoimmune diseases. Research biosimilar versions of all five are available for laboratory use. For a detailed comparison of how research biosimilars differ from originator drugs, see our Biosimilar vs. Originator guide.
In cancer research, TNF-α is studied in the context of: tumor-promoting inflammation (chronic TNF-α in the TME), TNFR2-mediated Treg expansion, TNF-α as a mediator of immune-related adverse events (irAEs) during checkpoint immunotherapy, and TNF-α neutralization to prevent irAEs while maintaining anti-tumor efficacy.
Recombinant TNF-α proteins are used in cell stimulation assays (NF-κB reporter, cytotoxicity), ELISA standards, and as positive controls for inflammatory cytokine measurement. For reconstitution best practices, see our Recombinant Protein Handling Guide.
TNF-α antibodies, recombinant proteins, and 5+ biosimilar anti-TNF formats
Available in unconjugated, HRP-conjugated, FITC/PE/APC-conjugated, and biotinylated formats. Recombinant proteins with His-tag and Fc-tag options. Research biosimilar reference antibodies for PK/ADA assays.
1. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31-46. doi: 10.1158/2159-8290.CD-21-1059
2. Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541-550. doi: 10.1038/s41591-018-0014-x
3. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423-1437. doi: 10.1038/nm.3394
67+ Research Reagents
Antibodies, recombinant proteins, and biosimilars. Original manufacturer quality.
Browse Products →All products are for research use only. For technical support, contact order@abinscience.com.
+86-27-65523339
Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский